1 BTC
=
- USD
TuHURA Biosciences, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Market Statistics
Trading Metrics
How to Buy HURA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy HURA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articles
TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.
Halper Sadeh LLC is investigating several companies, including MoneyLion Inc., Patterson Companies, Inc., TuHURA Biosciences, Inc., and Kineta, Inc., for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
The M&A Class Action Firm is investigating the proposed merger between Kineta, Inc. (OTC: KANT) and TuHURA Biosciences, Inc. The firm is looking into the terms of the agreement, where TuHURA would acquire the rights to Kineta's KVA12123 antibody.